Does Ozempic make you poop a lot? This is a common concern for patients prescribed semaglutide for type 2 diabetes. Ozempic affects the digestive system by slowing gastric emptying and altering gut motility, which can change bowel habits. However, the effect varies considerably between individuals—some experience diarrhoea and increased bowel frequency, whilst others develop constipation. Both are recognised as common side effects. Understanding how Ozempic influences your digestive system, what to expect, and when to seek medical advice can help you manage treatment effectively and maintain quality of life whilst achieving glycaemic control.
Quick Answer: Ozempic can cause either increased or decreased bowel frequency, with both diarrhoea and constipation classified as common side effects affecting individual patients differently.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus. The medication works by mimicking the action of naturally occurring GLP-1, a hormone that regulates blood glucose levels and appetite. However, GLP-1 receptors are not confined to the pancreas—they are widely distributed throughout the gastrointestinal tract, which explains why Ozempic commonly affects digestive function.
When semaglutide binds to GLP-1 receptors in the gut, it slows gastric emptying, meaning food moves more slowly from the stomach into the small intestine. This mechanism contributes to improved glycaemic control and increased satiety, but it also alters normal bowel patterns. The medication influences gut motility and the balance of digestive processes, which can manifest as various gastrointestinal symptoms. It's worth noting that this slowing of gastric emptying tends to diminish over time (tachyphylaxis) as the body adapts to treatment.
The most frequently reported digestive side effects in clinical trials include nausea, diarrhoea, constipation, vomiting, and abdominal discomfort. According to the Summary of Product Characteristics (SmPC) approved by the MHRA, gastrointestinal adverse reactions are typically mild to moderate in severity and tend to diminish over time. These effects are dose-dependent, meaning they often become more noticeable when the dose is increased during the titration phase.
Understanding that these digestive changes result from the medication's intended mechanism of action—rather than representing a malfunction—can help patients manage expectations. The gastrointestinal effects reflect Ozempic's systemic influence on gut hormone signalling, which is integral to its therapeutic benefit but commonly affects bowel function in many individuals.
The relationship between Ozempic and bowel frequency is complex and varies considerably between individuals. Diarrhoea is one of the most commonly reported side effects, classified as 'common' (affecting between 1 in 10 and 1 in 100 people) according to the MHRA-approved SmPC. For these individuals, Ozempic can indeed cause more frequent bowel movements, often accompanied by looser stools. This occurs because the medication alters gut motility and transit time.
However, it is equally important to note that constipation is also classified as a 'common' side effect. For these individuals, Ozempic has the opposite effect, reducing bowel frequency and causing harder stools. This paradoxical response reflects individual variation in how the gastrointestinal system responds to slowed gastric emptying and altered gut transit time.
There is no official evidence suggesting that Ozempic universally increases stool frequency in all patients. The medication's effect on bowel habits appears highly individualised, influenced by factors such as baseline gut function, dietary habits, hydration status, concurrent medications, and the specific dose being administered. Some patients report no significant change in their bowel patterns whatsoever.
The timing of digestive symptoms is also relevant. Gastrointestinal side effects, including changes in bowel frequency, are most pronounced during the initial weeks of treatment and following dose increases. As the body adapts to semaglutide, many patients find that their bowel habits gradually normalise, though this adjustment period can take several weeks. If you experience persistent changes in bowel frequency—whether increased or decreased—that interfere with daily activities or cause concern, this warrants discussion with your prescribing clinician to ensure appropriate management and exclude other contributing factors.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereEffective management of digestive side effects can significantly improve tolerability and treatment adherence. Dietary modifications represent the first-line approach for many patients. Eating smaller, more frequent meals rather than large portions can reduce the burden on a digestive system already slowed by Ozempic. Avoiding high-fat, greasy, or heavily spiced foods may help minimise nausea and diarrhoea, as these foods are more difficult to digest when gastric emptying is delayed.
For patients experiencing diarrhoea or increased bowel frequency, maintaining adequate hydration is essential. Drinking plenty of water throughout the day helps prevent dehydration, which can exacerbate fatigue and other symptoms. Consider oral rehydration solutions if diarrhoea is significant. Incorporating soluble fibre from sources such as oats, bananas, and rice may help firm stools naturally. Conversely, if constipation is the primary concern, gradually increasing dietary fibre from vegetables, fruits, and whole grains, alongside adequate fluid intake, can promote regular bowel movements.
The dose titration schedule plays a crucial role in minimising gastrointestinal side effects. Ozempic is typically initiated at 0.25 mg once weekly for four weeks, then increased to 0.5 mg weekly. Further increases to 1 mg or 2 mg should only occur if clinically indicated and tolerated. Rushing this titration or skipping steps increases the likelihood of troublesome digestive symptoms. If side effects are particularly problematic, your GP or diabetes specialist may recommend remaining at a lower dose for a longer period before escalating, or in some cases, temporarily reducing the dose until symptoms improve.
As per the SmPC, Ozempic should be administered once weekly on the same day each week for consistency. Over-the-counter remedies such as loperamide for diarrhoea or gentle laxatives for constipation may be appropriate in some cases, but these should only be used after consulting with a pharmacist or healthcare professional to ensure they are safe and suitable for your individual circumstances.
While mild digestive changes are common and often manageable with self-care measures, certain symptoms require prompt medical evaluation. Severe or persistent diarrhoea—defined as frequent loose stools lasting more than a few days—can lead to dehydration and electrolyte imbalances. Warning signs of dehydration include dark urine, dizziness, excessive thirst, dry mouth, and reduced urine output. If you experience these symptoms, contact your GP or NHS 111 for advice. Patients with existing kidney disease should seek medical advice earlier as they are at higher risk of acute kidney injury from dehydration.
Severe abdominal pain, particularly if it is persistent, worsening, or accompanied by fever, vomiting, or inability to keep fluids down, requires urgent assessment. Although rare, Ozempic has been associated with acute pancreatitis in a small number of cases. Characteristic symptoms include severe upper abdominal pain that may radiate to the back, nausea, and vomiting. If pancreatitis is suspected, you should stop taking Ozempic immediately and seek urgent medical attention. This constitutes a medical emergency requiring immediate evaluation in an emergency department.
You should also seek medical advice if you notice blood in your stools, black tarry stools, or unexplained weight loss beyond what is expected from diabetes management. Similarly, symptoms of gallbladder disease—such as pain in the right upper abdomen, fever, or yellowing of the skin or eyes—require prompt medical review, as GLP-1 receptor agonists have been associated with an increased risk of gallstones. These symptoms are not typical side effects of Ozempic and may indicate other underlying conditions requiring investigation.
If constipation becomes persistent or severe—accompanied by significant abdominal discomfort, bloating, or vomiting—medical review is warranted, especially if it doesn't improve with self-care measures. Persistent symptoms that significantly impair quality of life should prompt a medication review, even if they are not medically dangerous. According to NICE guidance on type 2 diabetes management, treatment should be individualised, and if side effects are intolerable despite appropriate management strategies, alternative therapeutic options should be considered. Your healthcare team can assess whether dose adjustment, additional supportive treatments, or switching to a different medication class would be more appropriate for your circumstances.
If you experience any suspected side effects from Ozempic, you can report them directly to the MHRA through the Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.
Yes, Ozempic can cause either diarrhoea or constipation, both classified as common side effects. Individual responses vary considerably based on baseline gut function, diet, hydration, and dose, with some patients experiencing no significant change in bowel habits.
Gastrointestinal side effects are most pronounced during the initial weeks of treatment and following dose increases. Many patients find their bowel habits gradually normalise as the body adapts to semaglutide, though this adjustment period can take several weeks.
Seek medical advice for severe or persistent diarrhoea lasting more than a few days, signs of dehydration, severe abdominal pain, blood in stools, or symptoms of pancreatitis. Persistent symptoms significantly impairing quality of life also warrant medication review.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
